Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 18;17(8):e0272945.
doi: 10.1371/journal.pone.0272945. eCollection 2022.

Exploration of Streptococcus core genome to reveal druggable targets and novel therapeutics against S. pneumoniae

Zeshan Mahmud Chowdhury  1 , Arittra Bhattacharjee  1 , Ishtiaque Ahammad  1 , Mohammad Uzzal Hossain  1 , Abdullah All Jaber  2 , Anisur Rahman  1 , Preonath Chondrow Dev  1 , Md Salimullah  3 , Chaman Ara Keya  2
Affiliations

Exploration of Streptococcus core genome to reveal druggable targets and novel therapeutics against S. pneumoniae

Zeshan Mahmud Chowdhury et al. PLoS One. .

Abstract

Streptococcus pneumoniae (S. pneumoniae), the major etiological agent of community-acquired pneumonia (CAP) contributes significantly to the global burden of infectious diseases which is getting resistant day by day. Nearly 30% of the S. pneumoniae genomes encode hypothetical proteins (HPs), and better understandings of these HPs in virulence and pathogenicity plausibly decipher new treatments. Some of the HPs are present across many Streptococcus species, systematic assessment of these unexplored HPs will disclose prospective drug targets. In this study, through a stringent bioinformatics analysis of the core genome and proteome of S. pneumoniae PCS8235, we identified and analyzed 28 HPs that are common in many Streptococcus species and might have a potential role in the virulence or pathogenesis of the bacteria. Functional annotations of the proteins were conducted based on the physicochemical properties, subcellular localization, virulence prediction, protein-protein interactions, and identification of essential genes, to find potentially druggable proteins among 28 HPs. The majority of the HPs are involved in bacterial transcription and translation. Besides, some of them were homologs of enzymes, binding proteins, transporters, and regulators. Protein-protein interactions revealed HP PCS8235_RS05845 made the highest interactions with other HPs and also has TRP structural motif along with virulent and pathogenic properties indicating it has critical cellular functions and might go under unconventional protein secretions. The second highest interacting protein HP PCS8235_RS02595 interacts with the Regulator of chromosomal segregation (RocS) which participates in chromosome segregation and nucleoid protection in S. pneumoniae. In this interacting network, 54% of protein members have virulent properties and 40% contain pathogenic properties. Among them, most of these proteins circulate in the cytoplasmic area and have hydrophilic properties. Finally, molecular docking and dynamics simulation demonstrated that the antimalarial drug Artenimol can act as a drug repurposing candidate against HP PCS8235_RS 04650 of S. pneumoniae. Hence, the present study could aid in drugs against S. pneumoniae.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. A schematic representation of the workflow involved to identify potential anti-streptococci drug targets.
Fig 2
Fig 2. Circular representation of the S. pneumoniae genome and related species.
The brown bar of the circular plot represents the core genes.
Fig 3
Fig 3. Categories of annotated S. pneumoniae hypothetical proteins classified according to their biological, molecular, and cellular functions.
Proteins involved in molecular functions were relatively higher compared to others.
Fig 4
Fig 4. Venn diagram representing the number of hypothetical proteins with virulence factor pathogenicity.
Fig 5
Fig 5. String results of PPI revealed several HPs that interact with pneumococcal vaccine antigen A and Ribosomal silencing factor; PCS8235_RS05845 and PCS8235_RS02595 have the highest nodes.
Fig 6
Fig 6
Interaction between the best drug for the HPs in S. pneumoniae and the active site amino acid residues of each of the HPs (a) PCS8235_RS04650- Artenimol (b) PCS8235_RS04650- Aspartate beryllium trifluoride (c) PCS8235_RS02820-2-(N-morpholino) ethanesulfonic acid.
Fig 7
Fig 7
RMSD analysis of (A) PCS8235_RS02820 (green) and PCS8235_RS02820-2-(N-morpholino) ethanesulfonic acid complex (purple) (B) PCS8235_RS04650 (red) and PCS8235_RS04650 –Artenimol (purple) and PCS8235_RS04650-Aspartate beryllium trifluoride (gray) at 100ns.
Fig 8
Fig 8
RMSF analysis of (A) PCS8235_RS02820 (brown) and PCS8235_RS02820-2-(N-morpholino) ethanesulfonic acid complex (blue) (B) PCS8235_RS04650 (blue) and PCS8235_RS04650 –Artenimol (golden) and PCS8235_RS04650-Aspartate beryllium trifluoride (green) at 100 ns.
Fig 9
Fig 9
SASA calculation of (A) PCS8235_RS02820 (golden) and PCS8235_RS02820-2-(N-morpholino) ethanesulfonic acid complex (green) (B) PCS8235_RS04650 (blue) and PCS8235_RS04650 –Artenimol (green) and PCS8235_RS04650-Aspartate beryllium trifluoride (red) at 100ns.
Fig 10
Fig 10
Rg measurement of (A) PCS8235_RS02820 (green) and PCS8235_RS02820-2-(N-morpholino) ethanesulfonic acid complex (red) (B) PCS8235_RS04650 (green) and PCS8235_RS04650 –Artenimol (red) and PCS8235_RS04650-Aspartate beryllium trifluoride (yellow) at 100 ns.
See this image and copyright information in PMC

References

    1. Ferreira-Coimbra J, Sarda C, Rello J. Burden of Community-Acquired Pneumonia and Unmet Clinical Needs. Adv Ther. 2020;37: 1302–1318. doi: 10.1007/s12325-020-01248-7 - DOI - PMC - PubMed
    1. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al.. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200: e45–e67. doi: 10.1164/rccm.201908-1581ST - DOI - PMC - PubMed
    1. Rudan I, O’Brien KL, Nair H, Liu L, Theodoratou E, Qazi S, et al.. Epidemiology and etiology of childhood pneumonia in 2010: estimates of incidence, severe morbidity, mortality, underlying risk factors and causative pathogens for 192 countries. J Glob Health. 2013;3: 010401. - PMC - PubMed
    1. Brooks LRK, Mias GI. Streptococcus pneumoniae’s Virulence and Host Immunity: Aging, Diagnostics, and Prevention. Front Immunol. 2018;9: 1366. doi: 10.3389/fimmu.2018.01366 - DOI - PMC - PubMed
    1. GBD 2016 Lower Respiratory Infections Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018;18: 1191–1210. doi: 10.1016/S1473-3099(18)30310-4 - DOI - PMC - PubMed

Substances